Fig. 2
From: CRISPR–Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics
Application of CRISPR–Cas9-mediated genome engineering in studying preclinical models as well as in editing clinical targets
Fig. 2 | Cancer Cell International